Drugs / Sabin strain-based inactivated polio vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03526978 | Aug → Oct 2017 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-08-07 | Sinovac Biotech Co., Ltd | Results SINOVAC科兴灭活脊灰疫苗与其他疫苗同时接种安全有效 sinovac.com ↗
研究结果表明，无论是单独接种还是与其他疫苗同时接种， SINOVAC科兴的sIPV大规模应用于儿童基础免疫和加强免疫时，均具有良好的安全性和免疫原性。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-07 | Sinovac Biotech Co., Ltd | SINOVAC科兴灭活脊灰疫苗与其他疫苗同时接种安全有效 sinovac.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sabin strain-based inactivated polio vaccine | “The Sabin strain-based inactivated polio vaccine (sIPV) plays a vital role in eradicating poliomyelitis in developing countries.” PMID 30958543 ↗ Oct 2019 |
| Known as | sIPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03526978 ↗ |
| Modality | Vaccine | “The Sabin strain-based inactivated polio vaccine (sIPV)” PMID 30958543 ↗ Oct 2019 |